HK Stock Market Move | INNOGEN-B(02591) rose more than 4% as its core product, Elesupagrulide , officially entered the commercial sales stage in Macau.

INNOGEN-B(02591) surged over 4%, as of the time of writing, it rose 4.42% to 46.3 Hong Kong dollars, with a turnover of 12.5852 million Hong Kong dollars. On the news front, INNOGEN-B announced that the company has been actively promoting the global expansion of its core product (Isupaglucose ) and received approval in June 2025 from the Macao Special Administrative Region of the People's Republic of China to treat type 2 diabetes (T2D) with the core product's Biologics License Application (BLA). The company's board of directors happily announced that on September 12, 2025, the first prescription for the core product for the treatment of type 2 diabetes has been issued at the Macao Huabo Medical Center, marking the official entry of the core product into the commercial sales stage in Macao.